

Prostate Cancer Genomic Test Overview

January 2018

| Test | Description | Validated endpoint(s) in a biopsy setting | Biomarker selection specific for prostate cancer | Patient's Specimen | Patient Access |
|-----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| oncotypeDX[®] <i>Genomic Prostate Score</i> <i>Genomic Health</i> | Genomic Prostate Score[™]: Predicts the likelihood of Prostate Cancer Death and Metastasis within 10 years after RP, and Adverse Pathology ¹ using multiple genomic pathways | <ul style="list-style-type: none"> • Adverse Pathology • Biochemical Recurrence, Prostate Cancer Death and Metastasis within 10 years after RP • High Grade Disease • Non-Organ Confined Disease | YES | Positive Biopsy NCCN [®] Very Low, Low, Favorable-Intermediate risk GS 3+3, 3+4 | Medicare Reimbursed for biopsy NCCN Very Low[†]/Low[‡] and Favorable Intermediate[§] Financial Assistance Available |
| Prolaris[®] <i>Myriad Genetics</i> | Cell Cycle Progression Score: Reports the risk of dying from untreated disease in ten years, using a single genomic pathway | <ul style="list-style-type: none"> • 10-year Untreated Mortality • Biochemical Recurrence • Metastasis after RP | NO | Positive Biopsy AUA [®] Low-High Risk | Medicare Reimbursed for biopsy NCCN Very Low/Low and Favorable Intermediate Financial Assistance Available |
| Decipher[®] <i>GenomeDx Bioscience</i> | Genomic Classifier: Predicts the probability of metastasis after surgery or radiation using multiple genomic pathways | <ul style="list-style-type: none"> • High Grade Disease • 10-year Metastasis after RP • Metastasis after radiation therapy | YES | Positive Biopsy NCCN Low-High Risk | Medicare Reimbursed in Post RP Only Financial Assistance Available |
| ProMark^{®*} <i>Metamark Genetics</i> | ProMark Score: Predicts likelihood of Adverse Pathology using protein staining | <ul style="list-style-type: none"> • Adverse Pathology • High Grade Disease • Non-Organ Confined Disease | YES | Positive Biopsy GS 3+3, 3+4 | Medicare Reimbursed for biopsy NCCN Very Low/Low Financial Assistance Available |
| ConfirmMDx[®] <i>MDx Health</i> | ConfirmMDx result: Predicts likelihood of negative repeat biopsy | Negative Repeat Biopsy | YES | Negative Biopsy HGPIN Biopsy | Medicare Reimbursed Financial Assistance Available |
| 4KScore[®] <i>Opko</i> | 4KScore: Provides probability of aggressive cancer on initial biopsy | Likelihood of GS 3+4 and higher at initial biopsy | YES | Blood Biopsy eligible patients | Financial Assistance is not reported on website |

National Comprehensive Cancer Network, NCCN, and NCCN Guidelines are registered trademarks of the National Comprehensive Cancer Network. NCCN does not endorse any therapy or product. AUA is a registered trademark of American Urological Association, AUA does not endorse any therapy or product. *ProMark relies on proteomic testing. 1.Adverse Pathology is defined as high-grade and/or non-organ-confined disease.



NCCN Prostate Cancer Guidelines (NCCN Guidelines Version 1.2017, page 7, footnote C)²

“Men with clinically localized disease may consider the use of tumor-based molecular assays. Retrospective case cohort studies have shown that the molecular assays performed on biopsy or prostatectomy specimens provide prognostic information independent of NCCN risk groups.”

[†]Gleason 3+3=6 (GG1): •PSA<20 •<cT1c-cT2a [‡]Gleason 3+3=6 (GG1): •PSA<10 •<cT2b-cT2c [§]Gleason 3+4=7 (GG2): •PSA<10 •cT1c-cT2a